Back to Search Start Over

Chugai Pharma seeks Japanese approval for humanized anti-CD20 monoclonal antibody, Gazyva to treat CLL

Source :
PharmaBiz. March 8, 2022
Publication Year :
2022

Abstract

Chugai Pharmaceutical Co., Ltd. and Nippon Shinyaku Co., Ltd. announced that Chugai filed a regulatory application with the Ministry of Health, Labour and Welfare (MHLW), for approval of an anti-cancer [...]

Details

Language :
English
Database :
Gale General OneFile
Journal :
PharmaBiz
Publication Type :
Periodical
Accession number :
edsgcl.696053428